Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.99 USD
-1.77 (-1.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $135.92 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
NBIX 135.99 -1.77(-1.28%)
Will NBIX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NBIX
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for NBIX
Promising Outlook for Neurocrine’s NBI-‘845 in MDD Market Based on Strong Phase 2 Results and Competitive Positioning
Buy Rating Affirmed for Neurocrine on Promising Phase 2 SAVITRI Study Results
Maintaining Hold on Neurocrine Amid Promising Yet Uncertain Clinical Developments
Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Neurocrine Biosciences upgraded at Wells Fargo on pipeline